Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Envisia Therapeutics, Liquidia Technologies, Lumos Pharmaceuticals, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals. Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board, Southeast Bio board, and the NC State Physical and Mathematical Sciences Foundation board.
Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.
- February 4